瑞士巴塞尔大区经济及创新促进局欢迎您

在瑞士最具活力的经济地区培育创新,加速业务发展  >>>>

最瑞士

瑞士是亲商、可靠和高效的代表。巴塞尔地区经济强盛,秉承明确的亲商核心价值,是瑞士这些美德的光辉榜样。  >>>>

生命科学和医疗行业第一

整个生命科学价值链汇聚于一处,且触手可及?这是700家及越来越多的公司对巴塞尔地区情有独钟,将其作为研发、生产和总部的原因。  >>>>

创新行业第一

多项研究结果表明,瑞士是全球最具创新精神的国家。巴塞尔地区丰富的知识、高素质国际人才和强有力的产业支柱使瑞士成为领先的创新枢纽。  >>>>

往来欧洲交通便利度第一

无论是集装箱运输还是空运,巴塞尔地区都拥有交通便利的优势。它与德国和法国接壤,位于欧洲中部的中心地带,是国际贸易青睐的物流枢纽和城市平台。  >>>>

文化和休闲第一

世界级艺术珍宝、文化和体育活动,融入健康自然娱乐景观中的国际化都市氛围,所有这些因素结合在一起,使巴塞尔地区成为全球最适宜居住和工作的地区之一。  >>>>

瑞士巴塞尔大区经济及创新促进局是瑞士西北地区巴塞尔乡村州、巴塞尔城市州和汝拉州为促进创新和经济发展而联合成立的机构。本机构旨在帮助国外企业家和公司在巴塞尔地区成功实践创新,创立公司。

我们拥有15,000名决策者、创新者、专家、影响者和增值者组成的广泛关系网络,让客户能直接获取相关专业知识和技术。

瑞士巴塞尔大区经济及创新促进局主要在以下四个领域内为客户提供定制化服务:

投资巴塞尔地区

提供个性化支持,帮助客户在巴塞尔地区择址。本机构将在整个择址和入驻过程中为公司提供中肯的建议。

为创新着牵线搭桥

帮助生命科学、医疗技术、信息通信技术(ICT)、微技术、纳米及材料和生产技术领域的公司和研究人员在技术、研发和创新事务方面建立联系。

支持创业

为计划在巴塞尔创业的企业家提供全面支持,在其商业计划的运营执行过程中进行协助。此外,以上技术领域中处于扩张模式的初创公司和中小型公司可从策略性交流服务中受益,与行业专家和投资人建立联系。

进驻中国

为瑞士西北部地区寻求扩张到中国的公司提供适当的合作伙伴网络,协助其顺利进驻中国市场,执行扩张项目。

瑞士巴塞尔大区经济及创新促进局还管理着一个综合性信息平台,展示巴塞尔商业地区的优势和专长领域,进一步促进该区域创新公司的融入:

创新报告

涵盖巴塞尔地区最新创意活动和报告,每月发布一次新闻简报,内容包含采访、背景故事和公司入驻本地的消息。

创新活动

瑞士巴塞尔大区经济及创新促进局每年组织并合办逾50次专门针对知识转移和创业文化的活动。在“创新活动”中,创新者和企业家分享他们最新的创新理念和经验。

在竞争力和创新能力方面,瑞士已多年位居世界顶级营商目的地前列。多个因素保证了瑞士的领先地位。除了优良的教育和先进的基础设施外,让瑞士等同于亲商、可靠和高效的另一个重要原因就是高效的瑞士政府机构。几十年来,瑞士强有力的法律系统、可靠的规划和稳定的金融体系使得在瑞士经营的公司及其在这里的投资项目都受益匪浅。这种环境也是企业向新市场持续扩张的一个最重要的前提条件。瑞士跨国公司密度全球最高绝非偶然。

巴塞尔地区对瑞士的成功做出了重大贡献。众多国际领先跨国公司不仅发迹于此,这些公司的成功也为该地区的经济增长注入强劲动力。例如,巴塞尔地区的GDP远高于瑞士全国平均水平。大巴塞尔地区人均国内生产总值为瑞士最高。与此同时,巴塞尔在生命科学和其他高科技领域的领先优势推动了瑞士创新能力的发展。例如,瑞士约有占总值五分之一的出口货物在巴塞尔地区制造,考虑到巴塞尔地区人口仅占瑞士人口不到10%,这是十分了不起的成就。

在全球商业、产业和知识竞争力方面,瑞士,特别是巴塞尔地区享有的美誉主要体现在以下四个突出优势上:

明智的税收政策

瑞士采用的联邦制度鼓励州与州之间的财政竞争,使税收保持在合理的范围内。除了联邦层面的统一税率外,各州可自主确定税率,并为公司提供最佳的营商环境。由此,巴塞尔地区的主要受益人是活跃在创新行业、具有高附加值的公司,以及大力投资研发和生产的公司。

自由的劳力市场

由于巴塞尔地区拥有众多活跃于国际的高科技公司,地方政府对于他们对海外高素质专家和高级管理人员的需求采取支持态度。这一欧洲最自由的劳动市场之一使得企业从中受益,同时也给予员工巨大利益。巴塞尔地区的劳动法规和劳力市场使得公司可以在营商环境发生变化并需采取相应措施时能够做出快速反应。

可持续的基础设施

在瑞士,火车晚点5分钟就会令人不快,但这种情况极少发生。这一点常令外国访客露出满意的笑容。众所周知,瑞士的公共基础设施堪称世界上最先进、最可靠的,而巴塞尔地区的优势正在于此。交通四通八达,通过公路、铁路和飞机航线可往返欧洲各地,通过莱茵河的水路可通向全球。

双轨制教育体系

瑞士仅三分之一的年轻人高中毕业后选择继续在瑞士顶尖大学深造。对于很多国家来说,这也许是教育体系的重大失职。但是实际上,这是瑞士在专业技术上成功的一部分原因。瑞士双轨制教育体系旨在确保大多数年轻人完成瑞士联邦认证的学徒期,以尽早参加工作。年轻人可以(也通常会)在瑞士技术学院或应用科学类大学获取专业学位,大多是在职学位。这为瑞士劳力市场稳定提供了经过多年在职培训的入门级雇员,这些人员可以在最具发展潜力的行业进行灵活就业,而雇主和行业实际上也需要这样的人才。此外巴塞尔地区的独特优势在于其拥有众多完善的国际学校,这些学校能够满足外籍人士及其子女的需求,帮助他们轻松融入当地。

作为唯一一个基于直接民主制的政治体系,瑞士在几百年里建立起独特的具有凝聚力的政治和社会文化。其特点是联邦制、自治和一致性,是稳定的政治和社会环境的基石,也是瑞士价值观的体现。巴塞尔地区政府及其民众的开放思想和进取态度,使其成为营商目的地的典范,为企业提供了优良的发展环境,推动企业不断发展壮大。

巴塞尔地区是生命科学领域全球最受欢迎的目的地之一,在欧洲更是无出其右。作为全球市场前三强的罗氏和诺华都是从巴塞尔地区起家,继而将业务拓展至全球。

与之类似的其他跨国公司也在巴塞尔建立了其中心业务分部,其中包括礼来、雅培和拜耳。Actelion、Basilea和Evolva等众多新入驻的公司以及Bachem和Polyphor这样高度专业化的公司使得巴塞尔形成完整的生命科学生态系统。并不令人意外的是,巴塞尔地区还演变成具有发展前景的初创公司钟爱的热点地区。

巴塞尔地区有共计700家生命科学公司,它们对该地区业已颇具活力的营商环境做出重大贡献。这些企业的持续成功主要基于以下三个因素:

生命科学行业是巴塞尔地区经济增长的引擎。这个行业在此生根发芽,且枝繁叶茂

巴塞尔地区生命科学行业的雇员共计3.39万名,每小时生产的产品和服务价值高达4.05亿美元。这使巴塞尔地区成为全球生产力最高的生命科学目的地。巴塞尔地区的生产总值也位居全球之冠:巴塞尔地区的产量全球最高,年产值达230亿美元。与此同时,巴塞尔地区每年获得60亿美元研发投资,是全球这方面数额最高的地区。本地生命科学使经济增长高于瑞士全国平均水平,这使得该行业在巴塞尔地区的声誉无可挑剔。

巴塞尔地区拥有各类人才和专家,而且人数众多

从研发、创办公司到制造、营销和分销,巴塞尔地区拥有一条完整的生命科学价值链,因此您能找到企业在各个发展阶段和各个职能所需的人才和专家。他们人数众多,且经验丰富。加上顶尖的研究机构,如巴塞尔大学生物研究中心(Biozentrum)、苏黎世联邦理工学院(ETHZ)生物系统科学与工程学院和弗雷德里希•米歇尔研究所(FMI),您大致可以了解到巴塞尔地区独特的生命科学资源组合的范围有多广。该地区有触手可及的资源、技术和人才,其深度和密度在全球范围都无可匹敌。这为未来创新提供了独一无二的肥沃土壤。

巴塞尔地区作为生命科学行业的创新标杆已有逾250年的历史

因此巴塞尔地区可谓是涉足生命科学领域历史最悠久的地区。从十九世纪中叶的工业丝带染坊到生物技术革命,巴塞尔的生命科学生态系统不断演进,并在行业的巨大发展中实现了自身突破。这一光辉故事将被续写。与其他曾经实现发展的生命科学中心不同的是,巴塞尔地区在过去几年一直保持稳定和持续的增长。该地区未来几年计划在公共和私人基础设施项目上将投入60亿瑞士法郎,因此下一个高增长期指日可待。

传统优势、强有力的产业支柱、深厚的研发和商业化专长,使得巴塞尔地区成为全球最为完善和成熟的生命科学目的地。您很难再找到另一个像巴塞尔这样适合在生命科学领域高效、可持续和成功地开发科研及商业项目的地区。

高科技是巴塞尔地区经济的推动力,并且是本地经济增长高于平均水平的保障。而且这种局势将持续下去。强有力的产业支柱、吸引全球人才和专家的国际化营商环境,加上瑞士世界一流的教育体系,使巴塞尔地区成为创新的理想环境。在这里,企业,尤其是医疗技术、信息与通信技术、精密机械以及化工业公司都将从该地区的以下特点中受益:                       

巴塞尔地区拥有深厚的高科技产业基础

巴塞尔城市州92%的产业附加值来自高科技公司。类似地,在巴塞尔乡村州和汝拉州,该比例远高于70%,因此高于瑞士60%的平均水平。而瑞士60%的平均水平已使其跻身于世界最具创新精神的国家之列。

巴塞尔地区是研发领域领头羊

瑞士私营部门的研发投资比例高达69%,在全球范围内都属于较高比重。其中40%来自巴塞尔地区,而本地人口仅占瑞士人口的10%。瑞士国内专利最多的十家公司中有五家的总部位于巴塞尔地区,它们是罗氏、诺华、科莱恩、先正达和Endress+Hauser。这也是为什么巴塞尔地区成为瑞士国内聘请研发人员最多的地区。

巴塞尔地区与全球紧密联系,吸引着世界各地的人才

巴塞尔70万居民中约有五分之一来自海外;当前外籍人士达到3.6万人。巴塞尔地区与德法两国接壤,每天有7万名跨境上班族从邻国流入。很难再找到一个地区,像巴塞尔地区这样在如此小的区域内拥有如此具有活力的国际商务氛围,并吸引着全球各地的专业人才汇聚一处。

世界一流的科学和学术教育

除了是强大的产业研发中心外,巴塞尔地区在欧洲学术界举足轻重。巴塞尔大学拥有2,000名教授和1.2万名学生,是欧洲历史最悠久的大学之一,位居全球100所大学之列。从巴塞尔地区乘火车,2小时内即可到达苏黎世联邦理工学院(ETHZ,在巴塞尔设有生命科学学院)和洛桑理工学院(EPFL)。这两所大学都是全球绝对一流的大学。巴塞尔地区(包括其交界国)数百公里范围内共有167家研究机构。此外,瑞士的双轨制教育体系和瑞士西北应用科学大学稳定提供训练有素的高技能专业人才。

研究和调查结果显示,瑞士多年来一直都是全球领先的创新地区之一。强有力的产业支柱、吸引全球人才的全面国际化营商环境,再加上瑞士学术和双轨教育体系,使巴塞尔成为瑞士的创新枢纽。巴塞尔地区的资源密度可谓独一无二:在巴塞尔地区,最高水平的科学表现、行业专长和技术,以及高素质的劳动力都触手可及。


早在罗马帝国时期,巴塞尔莱茵港口就是通向北海航道的最南端港口。1226年,博登湖和北海之间的莱茵河段上建成第一座桥梁(也是此后多年唯一一座),使得巴塞尔演变为重要的贸易枢纽。巴塞尔地区与德国和法国接壤,位于欧洲中部的中心地带,保持了其作为瑞士最重要交通和物流枢纽的领先地位,为本地产业和商业带来诸多利益。
此外,巴塞尔地区特别适合计划在欧洲建立全球总部,以及积极追求全球贸易新机遇的公司。巴塞尔地区具有以下独特优势:

巴塞尔地区是欧洲重要的交通枢纽

从市中心乘出租车或公交仅需15分钟即可到达巴塞尔机场。从该机场可到达欧洲、北美和中东的90多个目的地。集装箱从巴塞尔城的三个莱茵河港口发出,三天内可到达鹿特丹港,而后从那里运往全球各地。火车站每个小时就有一列开往瑞士所有主要城市的火车,如苏黎世(包括苏黎世国际机场)、伯尔尼、洛桑和日内瓦,以及莱茵河畔的各个经济中心(即弗莱堡、卡尔斯鲁厄和斯特拉斯堡)。乘坐高铁几个小时就可轻松便捷地到达欧洲各大都市和首都,如法兰克福、巴黎和米兰。

巴塞尔地区是瑞士领先的物流枢纽

巴塞尔的三个莱茵河港口吞吐量占瑞士外贸总量的12%,其中食品和农产品吞吐量高达84.2万吨。整个巴塞尔地区的外贸额占瑞士总量的三分之一。巴塞尔机场是瑞士领先的货运机场。这使得巴塞尔作为物流枢纽的地位名副其实。巴塞尔物流行业拥有2.3万名从业人员。990家物流公司落户巴塞尔地区,包括市场领导者DHL、Panalpina、Goldrand 和嘉里物流。这些公司可提供成熟的解决方案应对复杂挑战,例如在供应链管理方面,而这正是生命科学和化工业企业常常需要的。

巴塞尔地处欧洲中心位置,是国际贸易公司的理想之选

特种烟草制造商大卫杜夫、零售商Dufry、餐饮公司 Transgourmet 和国际清算银行等各类公司和机构凸显出在巴塞尔交易和提供的货品的多样性。因此瑞士第二大连锁超市Coop和第一大百货公司Manor都选择将总部设在巴塞尔地区。该地区同样是一系列国际贸易展会的重要举办地。每年举办的巴塞尔国际钟表珠宝展(BaselWorld)实现了国际名表和珠宝业的很大一部分销售额。而巴塞尔艺术博览会(Art Basel)则是全球最重要的艺术盛会。越来越多的国际消费品牌已发现巴塞尔作为贸易枢纽的优势,并将欧洲总部设在巴塞尔地区。其中就有美国著名时尚品牌Fossil、自行车制造商Cannondale和时装设计品牌Tally Weijl。

越来越多的跨国公司发现将巴塞尔作为其全球或欧洲总部的吸引力,特别是考虑到巴塞尔出色的连通性和运输系统以及本地在物流和国际贸易上的优势。老字号瑞士公司和初创公司都在利用这里处于欧洲中心所带来的优势。最后,巴塞尔地区毗邻德国和法国,与世界各地交流频繁,本地人口具有世界性,使得整个商业区域生机勃勃,持续增长。

早餐在德国,中餐在法国,晚餐在瑞士:巴塞尔地区地处三国交界处,具备都市化的国际商业氛围,与瑞士其他都市地区相比,人们可以以相对较低的成本享受无与伦比的生活品质。获奖建筑、历史悠久的市中心和从嬉皮士到经典风格的丰富精致的文化生活,都是巴塞尔地区良好城市生活方式的几大支柱。同时,成熟的公共交通系统可快速直达郊区和乡村居住区,以及那里的自然公园和休闲场所。

问一问新来者和新移民:巴塞尔不仅拥有瑞士最大的外籍人士社区,各种国际学校为他们的子女提供教育,而且是定居时间超过5年外籍人士比例最高的地区。原因不止一个:

每个人都能享有巴塞尔的城市生活方式和丰富的文化生活

巴塞尔的根基在罗马和凯尔特人时期就已打下。中世纪末尾至现代初期,该地区首次达到全盛。当然,巴塞尔并未止步于此。现今,巴塞尔繁荣的创意行业、各色当地美味餐馆,以及丰富的文化活动带来了生机勃勃的都市生活方式。在狂欢节时漫步风景如画、历史悠久的市中心,在新巴洛克风格的交响乐厅前停留,或在夏季到明斯特广场观赏户外电影——巴塞尔总是精彩不断。

到了巴塞尔,艺术爱好者就来对了地方

巴塞尔美术馆创立于1671年,被视作历史最悠久的公共社区艺术博物馆。根据伦敦泰晤士报的排名,该馆位列世界5大美术馆之一。另一吸引人的景点是拜尔勒基金会博物馆。该馆由意大利著名建筑师Renzo Piano设计。巴塞尔的另一个艺术重头戏是全球最大的艺术展——巴塞尔艺术博览会(Art Basel)。每年,艺术家、收藏家、画廊和拍卖行以及名流贵宾早早地就在日历里标出博览会举办的日期。他们中有些人会赶来欣赏巴塞尔剧院享誉全球的获奖演出(有歌剧、戏剧和芭蕾舞)。

巴塞尔地区总是充满了运动气息,而且不仅是在体育馆或沙发前的电机上

本地最受欢迎的巴塞尔足球俱乐部(FC Basel)在圣雅各布公园主场迎战欧洲足球顶尖赛事的对手。ATP巡回赛的一流选手参加瑞士室内网球锦标赛,其中包括本地超级球星罗杰·费德勒。在竞技场之外,巴塞尔民众也很热衷于运动。巴塞尔地区自行车使用率为全瑞士最高,包括骑车的上班族和在周边乡间无数自行车道上行进的骑行爱好者。跑步爱好者可在莱茵河两岸的无障碍通道跑步。越野滑雪爱好者可在汝拉州绵延数公里的缓坡上滑行。驱车2小时不到,高山滑雪者和雪板滑雪者就可达到瑞士阿尔卑斯山的原始山坡上。

在瑞士、德国和法国交界处,有各色吸引人的活动等着您

是参加阿尔萨斯的品酒会、巴登-符腾堡南部的美食盛宴,还是在汝拉州山峰上惬意地野餐?在巴塞尔地区,没有一小时车程里满足不了的需求。而且,总会有新发现!想在炎炎夏日跳进沁凉的河水中吗?这时,莱茵河岸线将成为名副其实的地中海里维埃拉——就在巴塞尔市中心。

唾手可及的各色活动、无与伦比的一流公共交通基础设施、安全和稳定的政治局势使得瑞士经常位居生活质量调查排行榜前列。这些都能在巴塞尔地区轻松获得,而艺术文化、生活方式和国际氛围更是锦上添花。因此不足以为奇的是,巴塞尔被瑞士年轻人视作瑞士最具嬉皮士精神和最时尚的地区之一。

我们的服务
Gabriela Güntherodt

您的联系人

Gabriela Güntherodt

Head of International Markets & Business Affairs, Member of the Management Board

联系我们

投资巴塞尔地区

您的公司正在扩张吗?您正计划立足欧洲和瑞士,借以打入新市场吗?如是,那么巴塞尔地区正是您的理想之选。您将发现让您长久立于不败之地的要素近在咫尺。

众多跨国公司(主要是生命科学领域)确保了真正国际化的商业环境。巴塞尔地区拥有具有国际思维的人才库,整条价值链和各个职能环节都有高技能人才。巴塞尔地处欧洲中部,毗邻法国和德国,因此可以提供良好的商业环境,以及瑞士闻名于世的生活品质。

您想了解在此地区投资的好处吗?我们很乐意为您展示。我们的专家将在贵公司扩张项目的各个阶段为您提出全面而专业的建议。

评估

税务?就业市场?竞争对手?政府许可?产业环境?我们将根据您独特的项目要求,收集巴塞尔地区及瑞士的所有相关信息和数据。

选址

有任何待解决的问题?我们将寻找合适的专家为您答疑解惑。我们会将您介绍给政府机构、行业和法律专家,并在您置业的过程中提供专业支持。

实地考察

您想亲自了解巴塞尔地区吗?我们将完全根据您的需求精心定制一份高效的实地考察计划和行程。

商业开发

您想让公司业务增长提速吗?我们将帮助您建立与本地合作伙伴和机构之间的联系,加快您进驻巴塞尔地区高度多样化商业和创新生态系统的步伐。                                      

我们的服务将免费提供给那些正考虑择址巴塞尔的公司,这也有助于营造充满活力的商业环境。创新和接受新理念的开放心态是巴塞尔地区的悠久传统。我们期待听取您的商业理念,并协助您一开始就取得成功。

Gabriela Güntherodt

您的联系人

Gabriela Güntherodt

Head of International Markets & Business Affairs, Member of the Management Board

联系我们
Frank Kumli

您的联系人

Frank Kumli

Head of Innovation & Entrepreneurship, Member of the Management Board


Tel. +41 61 295 50 19

frank.notexisting@nodomain.comkumli@baselarea.notexisting@nodomain.comswiss

为创新者牵线搭桥

“为创新者牵线搭桥”服务将创新构想、企业和企业家召集在一起。该服务有两种形式,一种是瑞士巴塞尔大区经济及创新促进局组织的非正式的专家活动,另一种是正式的针对性支持服务,为具体项目提供专家、合作伙伴和融资。我们的专家拥有8000多名创新者组成的强大网络作为后盾。

“为创新者牵线搭桥”服务主要面向以下五大核心主题领域:生命科学、医疗技术、信息与通信技术、生产技术和微技术、纳米技术和材料。每个技术领域都由一名专家专门负责。技术领域经理与行业展开密切合作,制定活动计划,担任项目的联系伙伴,与巴塞尔地区相关研究机构和其他机构培养伙伴关系。

因此,“为创新者牵线搭桥”服务为客户提供了立足于巴塞尔地区、从其多样化创新生态系统受益的理想入口。企业家、创新者和专家每年在逾50场活动上汇聚一堂,定期交流理念和知识,活动形式多种多样:

专题活动:专注于知识转移,为公司、特别是新创公司提供介绍公司和项目的机会,促进巴塞尔地区的创新者进行跨公司和跨学科的经验和知识交流。
研讨会:以拓展新技术应用范围以及发起具体项目和合作企业为目的,通过加强各个公司和学科的专家之间的对话,深度探讨某个主题。
技术与创新圈:运行多年的创新举措,目的是在各个公司和学科所组成的社区中进一步开发主题,以及探索新的市场潜力。

瑞士巴塞尔大区经济及创新促进局的支持创业服务为处于初创阶段的企业提供针对性的活动和服务。

Frank Kumli

您的联系人

Frank Kumli

Head of Innovation & Entrepreneurship, Member of the Management Board


Tel. +41 61 295 50 19

frank.notexisting@nodomain.comkumli@baselarea.notexisting@nodomain.comswiss
Sébastien Meunier

您的联系人

Sébastien Meunier

Director Industrial Transformation and Entrepreneurship

联系我们

支持创业

您正计划创业?这太好了,因为巴塞尔地区以创业为生。瑞士巴塞尔大区经济及创新促进局作为巴塞尔地区创新和外来投资的推进机构,为技术和创新领域的企业家提供支持。

我们服务的核心内容是研讨会及工作坊项目:

  • 创始人课程:扶持性服务的核心内容是我们的研讨会及工作坊项目。“创始人课程”基本套餐的目标群体是计划创业的所有意向方。可在此浏览其他课程的概述:课程概述

    更多服务是专门针对在创新和科技领域有具体项目的初创公司和企业家:
     
  • 企业家研讨会及工作坊:在这些活动中,可以就各种商业问题,例如商业计划、融资、产品开发、定价和知识产权,以及营销与沟通进行深入探讨。这一系列活动专门针对有具体创新项目的初创公司和高科技中小型企业。

    除了培训课程和研讨会之外,瑞士巴塞尔大区经济及创新促进局还提供针对具体项目的单独咨询服务。该咨询服务专门针对创新和科技领域增长潜力巨大的公司和项目。
     
  • 联系与咨询:在初期咨询中,我们的专家将评估对支持的需求,并与专业人士、研究机构或潜在合作伙伴建立联系。
  • 新企业评估:在有专人指导下的流程和单独召开的专家会议中,初创公司和创新型中小企业可以请知名的行业专家、企业家和投资人对其商业项目进行评审。更多信息

    瑞士巴塞尔大区经济及创新促进局的服务涵盖创业的初期阶段。目标是在初期构想到实际创业,再到首个实施计划和融资的过程中,提供宝贵信息和切实的建议。这不仅给予企业家更多安全保障,而且可以显著加快他们实施项目的速度。
Sébastien Meunier

您的联系人

Sébastien Meunier

Director Industrial Transformation and Entrepreneurship

联系我们

关于瑞士巴塞尔大区经济及创新促进局

 

瑞士巴塞尔大区经济及创新促进局是促进巴塞尔城市州、巴塞尔乡村州和汝拉州的创新和外来投资的机构。它由三个组织在2016年合并而成,即巴塞尔大区经济促进局、瑞士i-net创新网络和中国商务平台。
该局现有20名雇员,其500万瑞士法郎的年度预算由这三个州和国家经济事务秘书处(SECO)承担。


使命
瑞士巴塞尔大区经济及创新促进局的核心职能是促进巴塞尔地区作为商业中心的优势,以支持瑞士和外国企业家及其公司在该地区实施创新和商业项目。
该局提供的服务主要是为了持续发展和维护合格决策者、创新者、专家和传播者网络。在该网络的基础上,瑞士巴塞尔大区经济及创新促进局为客户提供有针对性的知识和技能。


服务
瑞士巴塞尔大区经济及创新促进局主要在以下三个领域内为客户提供专业服务:

  • 投资巴塞尔地区:为客户提供个性化的决策支持,协助他们在巴塞尔地区开设经营机构,为他们在整个设立过程中提供专业建议。
  • 为创新者牵线搭桥:为生命科学、医疗技术、信息通信技术(ICT)、微技术、纳米及材料和生产技术领域的企业和研究人员提供技术、研发和创新支持。
  • 支持创业:为那些计划在入驻巴塞尔地区或创办公司的企业家提供项目运营执行方面的一般性援助。此外,以上技术领域的初创公司和扩展中的中小企业还将获得支持,针对性地与专家和投资者建立关系网络。

渠道
为了支持这些服务,瑞士巴塞尔大区经济及创新促进局运营一个综合性信息平台,从而为巴塞尔地区保持领先的创新和商业中心地位做出贡献。为此,该局特别开设了两条渠道:

  • 创新报告:巴塞尔地区创新现场报告以及月度简报,内容包括采访、背景报告和在巴塞尔地区创立和开设公司的信息。
  • 创新活动:在每年逾50个知识转移和创业主题活动中,瑞士巴塞尔大区经济及创新促进局为创新者和公司创办人提供机会,就现有问题进行沟通和关系联络。
Sébastien Meunier

您的联系人

Sébastien Meunier

Director Industrial Transformation and Entrepreneurship


Tel. +41 61 295 50 15

sebastien.notexisting@nodomain.commeunier@baselarea.notexisting@nodomain.comswiss

我们的渠道: 活动|博客

report BaselArea.swiss

Switzerland Innovation Park Basel Area opens site in Jura

22.10.2019

Switzerland Innovation Park Basel Area has opened its third location. The park is now represented in Jura alongside its locations in the Cantons of Basel-Landschaft and Basel-Stadt. This represents something of a milestone for the operators BaselArea.swiss.

Switzerland Innovation Park Basel Area is now represented in all three supporting cantons of the operators BaselArea.swiss. Following on from locations in Basel and Allschwil BL, a third location was opened in Courroux. Domenico Scala, President of BaselArea.swiss, described this milestone: “We have now successfully closed the circle”.

The new location will focus on the field of medical technology, health technology, digital health and industrial transformation. A usable area of 1,200 square meters will be available for these pursuits. SMEs and start-ups will be able to use the office space to further develop their visions and secure success. In addition, BaselArea.swiss is offering relevant support programs to this end in the form of DayOne and i4Challenge. The first companies are already moving in to the Switzerland Innovation Park Basel Area, for example the software development company NextDay.Vision, which is based in Jura. In November, the start-up Ersys, which is active in the field of system ergonomics, will follow NextDay.Vision’s suit. The Research and Development Center for Micro and Nanotechnology CSEM will be offering consultancy from November onwards at the new location. At the same time, a total of 1.6 million Swiss francs is being invested in the expansion of the two floors of the building, which will be of benefit to the Jura economy.

The Canton of Jura has also been supporting the creation of this new location right from the very beginning of the projects. Jacques Gerber, President of the Jura Cantonal Government and Minister of Economic Affairs and Healthcare, has indicated that the Jura economy can flourish on the back of the Switzerland Innovation Park Basel Area by tapping into the innovation ecosystem. Moreover, Claude-Henri Schaller, Head of the Cantonal Office for Economics and Labor, commented: “We have poured all our energy into offering the best-possible framework conditions for the Jura economy. I think that we have managed to meet these requirements”.

report Life Sciences

Basel professor receives Latsis Prize

15.11.2019

event Industrial Transformation

Expert workshop - Machine Learning

Date: 15.11.2019

Place: Switzerland Innovation Park Basel Area, Site Jura, Place des Sciences 2, 2822 Courroux

report BaselArea.swiss

GRID boosts innovative power of Basel region

26.09.2019

Work on the construction of the GRID complex for innovation and commerce has begun on the BaseLink site in Allschwil BL. By mid-2022, the Switzerland Innovation Park Basel Area will be operating from the new site as its anchor tenant.

With the GRID (Grand Réseau d’Innovation et de Développement) and the neighboring newbuild of the Swiss Tropical and Public Health Institute, the ecosystem of the Basel region will be further expanded in the fields of life sciences, biotech, public health and medtech, it was reported in a press release from the Switzerland Innovation Park Basel Area, its operator BaselArea.swiss and Senn Resources AG. The latter has been tasked with constructing the GRID building designed by Basel architecture firm Herzog & de Meuron.

In this building, the GRID Campus of Collaboration, space will be created on five floors and an area of around 50,000m2for “offices and laboratories for teaching, research, development and production of innovative products for the future”. To this end, 150 million Swiss francs is being invested. By mid-2020, the Switzerland Innovation Park Basel Area will have given up its existing location in Allschwil and leased 6,000m2 at the GRID complex. Tenants are expected to have been found for the remaining space as well by this point. The goal is for the GRID to offer workplaces for 2,220 people.

The GRID will further enrich the area around the Bachgraben, which is already home to companies such as Actelion and Idorsia as well as institutions in the fields of life sciences, biotech, public health and medtech. A new building for the Swiss Tropical and Public Health Institute will also be constructed in this area. The GRID will contribute to “the Basel region further gaining significance as a first-class ecosystem for innovation”.

Allschwil is the largest of the three planned sites making up the Switzerland Innovation Park Basel Area, with the second in Basel and plans to create a third in Delémont. The Switzerland Innovation Park Basel Area is one of five locations in the network of Switzerland Innovation Park. It is backed by the two Basel cantons, Jura, the Handelskammer beider Basel and the University of Basel. 

report Invest in Basel region

Jura has plenty of greenfield sites

14.11.2019

event Entrepreneurship

Kickoff für startup baselland

Date: 19.11.2019

Place: FHNW Campus Muttenz, Hofackerstrasse 30, 4132 Muttenz

report BaselArea.swiss

“The Switzerland Innovation Park Basel Area and the Jura are a match made in heaven”

26.09.2019

The Switzerland Innovation Park Basel Area will be opening its Jura site on 25 October. Claude-Henri Schaller, Director of the Office for the Economy and Labour and Vice President of Switzerland Innovation Park Basel Area AG, is convinced that the Innovation Park can make a major contribution to the diversification of industry in the Jura and will create stronger ties between industry and research.

BaselArea.swiss: Is it fair to say that the Jura is a watchmaking canton?

Claude-Henri Schaller: I would go as far as to say that there is no such thing as a Swiss watch that isn’t at least partly made in the Jura. The watchmaking industry was the first sector to become established in the Jura – and it still defines the canton today. Currently, around 44 percent of jobs in the Jura are in the secondary sector, more than in any other canton. The international groups Swatch, Richemont, LVMH and Festina all have production sites in the Jura canton. Rolex also works with a lot of local suppliers. But our businesses are also applying their watchmaking expertise to other fields. The medtech sector is growing in importance here.

Is its strong focus on the precision engineering industry a strength or a weakness for the Jura canton?

The canton’s heavy reliance on the industry has pros and cons. On the one hand, export problems have a direct and marked effect on us. On the other hand, when the economy is booming we quickly feel the effects. The economic cycles in the Jura are shorter than in other regions. The unemployment rate can rapidly go up, but can quickly fall again. And we put our extensive expertise in precision engineering to good use in the medtech, mechanical engineering and aviation technology sectors. But our aim is to encourage further diversification in the businesses here.

Why is diversification so crucial to the Jura?

If the watchmaking industry is going through a bad patch, businesses need to have other options for growth and winning new markets. Diversification also creates other societal and economic opportunities: we are currently investing heavily in advanced skills training – we have one of the highest graduate qualification rates in the country. But this investment is not currently paying the dividends we would have liked. By fostering innovation in the Jura canton we are creating opportunities in the fields in which we excel. That enables our businesses to grow – and has positive repercussions for society as a whole. We want to ensure that our highly qualified workforce stays in the Jura or comes back to us.

So there’s room for improvement. Where does the canton intend to start?

In an SME, the boss does more or less everything themselves – carrying out research, generating sales, searching out innovation and new markets. Currently, companies are doing their research and development in house, usually behind closed doors. They are very secretive about it. Although we have the Haute Ecole Arc Neuchatel Berne Jura, we don’t have a research centre specifically for industry. That means that at the moment we’re not getting involved in research early enough or closely enough. But innovation is not about universities or businesses working alone any more. To come up with innovative solutions, industry and academia must work together more closely. The Jura site of the Switzerland Innovation Park Basel Area is an important building block in this.

In what way?

The political authorities in the Jura canton are pursuing three goals. We want to encourage innovation, support the diversification of industry and foster collaboration between research centres and businesses. With the Switzerland Innovation Park Basel Area now in the Jura, we have the opportunity to improve the research infrastructure and create closer ties between business, research, science and technology universities and the canton.

What role will the Innovation Park in the Jura play?

The Switzerland Innovation Park Basel Area has sites in Basel, Allschwil and now in Courroux in the Jura canton. The site here has the potential to become an enabler, promoting and organising links and projects at supracantonal level. A Jura-based company is now perfectly able to start up a project with Basel University Hospital on the Allschwill site, while a Basel-Stadt project can also make use of the resources in the Jura. With its specialisation, the Jura is a valuable addition to the expertise available in the Basel region. That’s also promising when it comes to developing new products.

How will you convince businesses to collaborate more and to use the Innovation Park in the Jura?

To reach as many SMEs as possible, we are working closely with the Chamber of Commerce, and together with BaselArea.swiss we have formed an advisory board. It’s up to representatives from industry and research to engage with the process of mutual exchange. Of course, we also need to keep businesses informed, working hard to explain the options open to them. The Switzerland Innovation Park Basel Area is of course all well and good as a political initiative, but the proof of the pudding lies in tangible projects and results. That’s why our job now is to identify, organise and see through suitable projects.

What sort of projects does the Jura site of the Switzerland Innovation Park Basel Area have in mind?

The innovation park concept is eminently suited to the Jura and our economy. Our businesses are keen to discuss concrete projects, and by working with research institutes they can get them up and running. On the Jura site of the Switzerland Innovation Park Basel Area, we are initially concentrating on the healthcare sector. We’re looking at how to improve the organisation of the healthcare sector in the surrounding regions. This may entail innovative processes or new solutions. One project is tackling the shortage of doctors. We are working with nursing staff to come up with innovative solutions for how nurses can take on a wider remit. I am convinced that the healthcare industry has enormous potential for the future. Other projects under the Industry 4.0 banner are set to follow.

What makes you think the Jura site of the Switzerland Innovation Park Basel Area will be a success?

There’s been an awful lot of interest in creating an Innovation Park in the Jura, much of which has come from businesses. Our first tenant, the IT security firm NextDay.Vision, signed up even before we were open. And we have all the skills required to run an innovation park. In addition, BaselArea.swiss is firmly established in the canton. A network is already in place. I am confident that with the Switzerland Innovation Park Basel Area we can get something good going here. What’s more, the Innovation Park’s remit is not just to help Jura-based businesses work together – we are open to the entire Basel region. I am very optimistic. The Jura already has a far-reaching reputation for its industrial know-how, and that’s something the Innovation Park can build on.

Interview: Annett Altvater

report ICT

Ist Ihre ICT bereit für die digitale Transformation?

14.11.2019

event Entrepreneurship

Boston / Basel / India Summit - Global Excellence in Life Science Entrepreneurship

Date: 19.11.2019

Place: Roche Turm (Bau 1) Grenzacherstrasse 124, 4070 Basel

report Life Sciences

"We make no compromises in creating the highest potential company"

26.08.2019

Versant Ventures has a strong history in building successful companies such as Therachon, Black Diamond or CRISPR  Therapeutics. We talked to Alex Mayweg, partner at Versant Ventures in Basel, about the beauty of Versant Ventures discovery engine Ridgeline Therapeutics, translating science into successful drug development programs and the future of drug discovery.

Alex, what does Versant Ventures do?

Alex Mayweg: Versant Ventures is a leading global venture fund focused on biotech that is excelling in early biotech investment and company creation. We have just celebrated 20 years in the business. Our strategy is to source the most innovative opportunities globally that could revolutionize the healthcare industry. We have three ways to build companies: One way is to invest in existing companies, together with others. However, in 50 percent of the opportunities, we create and initially finance the company all by ourselves. On top of that, we also operate discovery engines, such as Ridgeline Therapeutics – where we incubate the science, elaborate, and address the risks to then translate it into drug discovery programs and companies. To that end, we have assembled some of the best drug discovery professionals in the industry who help build the companies and science and may also end up moving into the newly created companies as they grow.

Versant Ventures has its headquarters in San Francisco and runs offices in the USA, Canada – and in Basel. Why the Basel area?

Versant has a strong track record in Europe. We have funded a number of successful companies here, like CRISPR Therapeutics or Therachon that was recently acquired by Pfizer. Thanks to our long established Basel office and our discovery engine that we launched three years ago, we can now harness the tremendous drug discovery expertise that exists in the region directly. Thousands of drug discovery professionals live here. This is unlike any other area in Europe and I think that makes the region very competitive globally. We have already committed up to 100 million dollars to the Basel area companies that we created through our discovery engine Ridgeline. We are very dedicated to the region, yet some companies may also have to grow up in the US. Many of our companies have dual footprints.

How does Ridgeline work?

The discovery engine is a team of excellent people who are creating companies that use Ridgeline as a resource and for support to be built. It’s a beautiful model. We create big vision companies that eventually become independent that initially have the support of people that know what they are doing to create a strong data set and come up with the right strategy. In this model we can attract talent that is hard for small startups to attract at an early stage. We have a great mix of biologists, cell biologists, cancer biologists, immunologists and chemists with both deep and broad experience in their fields.

What realm do you cover with your discovery engine?

We are agnostic when it comes to modalities. We have companies focused on small molecules and on proteins. Antibodies are incredibly powerful modalities, but we haven’t found the opportunity that has exited us so far. We are also seeing opportunities in cell therapy and other modalities emerging in this region. It would be very interesting for Switzerland to put a footprint down in this area as I see increasing activity and excellent science here.

Where do you find the science that excites you – or does the science find you?

It’s a mix of both. We identify themes that we feel are going to be important and we actively look for the academics with programs in those themes. We have to play to the future and look for the top quality academics in these areas. Very often, we find them in Europe and in Switzerland not too far from our front door.

Academics are often attached to their science. Versant is known to bring its own people into company creation. How do you handle that potential area of conflict?

It always amazes me where people can develop to, what they can learn and how they stretch in their careers. We want to be incredibly supportive of that. Yet, drug discovery is hard and you do need experience and a few scars from failed programs to be effective. If you don’t use your experience and don’t set up the right strategy you might apply the technology on the wrong thing. The combination of engaged academic founders, entrepreneurs with teams of smart and experienced drug discovery professionals and leadership has been very successful. That of course also means that Versant takes on an important role in company creation.
We make no compromises in creating the highest potential company in a given space. We are thinking big and I think it’s that appreciation of what it takes to build such a company. With over 150 companies in Versant’s experience, the firm can draw on a lot of knowledge on how to do this.

You were working in drug discovery at Roche before joining Versant Ventures. What is different in discovering drugs for a venture fund?

Roche is a terrific place for drug discovery – in fact I learnt most things about drug discovery there. Venture-backed biotech is a very different experience. We see hundreds of innovative technologies a year, and the opportunity to select the most compelling discoveries and build them into drug discovery companies is incredibly exciting. We invest into the latest innovation and technology with small but focused teams at an early stage. The capital availability nowadays is incredible, and you can now launch and operate full-fledged drug discovery programs outside of big pharma with experienced teams and through contract research organizations which was impossible in this way ten years ago.

How much capital does Versant invest before you do a big external round?

We reserve tens of millions for our companies, always depending on the company, on how we put that capital to work and how we allocate it. If the company or technology has capital demands that we alone cannot deliver we might bring in other investors already earlier. I would say that we are able to seed companies with significantly more capital than is the norm in this region.

Your fund sizes seem to become bigger and bigger. Why is that?

Deep pockets are needed to create leading companies, and when the technology is so broad that there are multiple applications, you don’t want to drip-feed these opportunities. It is hard and expensive to do drug discovery. We see companies who are convinced that they can get a molecule in the clinic with three million in seed capital. We know they will need much more than that. At the same time, we do not raise mega funds and the VC-backed biotech model does bring efficiencies of how we use capital to create value.

What is your first take once you decide to invest?

We de-risk the company and explore strategies, meaning among others that the science needs to be reproducible in an additional set of hands. We are involved at an early stage, which allows us to judge the scientific risk really well. Having a close proximity has the advantage of understanding and of becoming a big proponent of the science. Scientists have a tendency to fall in love with their science but if Versant is convinced and validates the science too, that is a tremendous advantage in raising additional capital and bringing in next-round investors.

Is failure an option?

Attrition is almost defining the pharma industry. In big pharma you start with 50 programs, they go down to 30, then to 10 in the clinic. You always weed out programs. Interestingly, attrition of companies in our portfolio is quite low. However, science is science, and programs don’t always work. We always plan drug discovery from A to B as a straight line and yet whenever you travel it’s a winding path. What you initially set out to do you may not end up doing. Yet, the venture model always tries to maximize, preserve and leverage the value built. It rarely happens that you let things sit and decay.

What do you expect from the future of biotech?

Look at the history of drug discovery innovation that came out of the chemical industry in the Basel area. There are innovation curves that extend over decades. Past innovation cycles have extended human life and cancer survival, have lowered heart disease death rates and completely plummeted infectious disease rates. We live in an incredible time in biotech. Years ago, it was small molecules and then antibodies emerged. Now we have the full breadth of modalities including small molecules, biologics, cell therapy, gene editing, gene therapy and others, unlocking an enormous amount of innovation potential. Besides choosing the best opportunities in existing innovation curves, we also aim to invent new curves. As one of my partners at Versant recently said: The coolest technology is one that hasn’t even been invented yet, but we can promise one thing: When it gets invented we are going to source it and build an amazing company around it.

If you want to learn more on how Versant Ventures operates and its discovery engine Ridgeline Therapeutics, join us in Basel for Alex’s presentation on 18 September: Investor Spotlight: Ridgeline Therapeutics – A Versant Ventures Discovery Engine

report Precision Medicine

Vaximm is using AI to develop cancer vaccines

12.11.2019

event Entrepreneurship

Atelier Business Model Canvas

Date: 22.11.2019

Place: Switzerland Innovation Park Basel Area, Site Jura, Place des Sciences 2, 2822 Courroux

report Industrial Transformation

"I am amazed by the level of innovation in the Jura"

11.06.2019

The Switzerland Innovation Park Basel Area already has two sites, in Allschwil and Basel, and will soon add a third in the Jura. It will be located on the Innodel campus in the municipality of Courroux, between Delémont and Courrendlin. Work is ongoing at the Jura site, which is set to officially open on 25 October.

This will be the culmination of a huge amount of work by various regional stakeholders as part of an ambitious federal project. The aim is to boost research and development in the region in particular and in Switzerland in general, as Frank Kumli, Head of Innovation & Entrepreneurship at BaselArea.swiss says in the interview with "Le Quotidien Jurassien".

Le Quotidien Jurassien: What's the significance of the new Jura site for Switzerland Innovation Park Basel Area?

Frank Kumli: It's a step forward for regional innovation. Like the others, the park will be dedicated to accelerating innovation. The Jura will finally be able to participate in the innovation park. It's very important to us for the Jura to be able to join us and for us to be able to draw on the region's skills and knowhow, while at the same time supporting local economic development and innovation. For us at Switzerland Innovation Park Basel Area, it's a unique opportunity to lead and support this Jura site.

What are your expectations for the Switzerland Innovation Park in the Jura?

Naturally, we hope it will be a vibrant site, where lots of things happen, where people come together to develop new ideas, discuss ideas and launch innovative projects. It should be an interface between the three cantons of Basel-Stadt, Basel-Landschaft and Jura in the field of innovation.

How many workstations will there be on this site?

In total, we will have a floor space of 1,200 m2, which could equate to sixty or so workstations, some split, so around 30 to 35 jobs.

Has there been any interest yet?

We are working closely with the Jura Chamber of Commerce and Industry, and its director, Pierre-Alain Berret, to promote the innovation park to heads of local SMEs. Several are interested in participating. Local and French start-ups have also expressed interest in setting up at the site.

And what about educational establishments?

On the academic side of things, we have also received interest from the Swiss Center for Electronics and Microtechnology (CSEM), which will have a presence on the site. We have also had discussions with Haute Ecole Arc (HE-Arc) locally to see how we can represent them on the site. We're in the process of signing some contracts. The aim is to have a mix of start-ups, some academic projects and, above all, lots of business projects.

What areas will the Switzerland Innovation Park Basel Area in the Jura be active in?

We will have projects in two areas: healthcare and business agility. We're not going to reinvent watchmaking. Instead, we’ll see how local businesses can be transformed, how they can become more agile in responding to the challenges of a changing world. For healthcare, we're working closely with the Jura Hospital and its director Thierry Charmillot, as well as the head of the Jura's Public Health Service, Nicolas Pétremand.

What exactly are you going to do in the field of health?

A consultation exercise is underway with Professor Hans-Florian Zeilhofer of Basel University Hospital. We have several projects planned with him. Professor Zeilhofer specialises in robotics and automation in surgery. He is convinced that there is a great deal of know-how in the Jura that can be put to use in this field. He is already cooperating on projects in the Jura, specifically in the field of 3D printing. With home automation, the idea is to make the home environment safe so that patients can be discharged from hospital more quickly, while also delaying their move to care homes, therefore maximising their time in their own home.

How long do you think it will take to hit your stride?

We're relatively optimistic, given the help that we are receiving from the Chamber of Commerce, the Jura Hospital, the Public Health Service and universities. I think that we should hit our stride in about a year's time, not in terms of jobs total but in terms of having a vibrant site with lots of innovative ideas. We've had lots of help locally to help find the right projects quickly.

What will be developed as part of industry 4.0?

For us, industry 4.0 is, of course, about production technologies. We're going to focus on agility, with an emphasis on the human aspect, teams, business models and, in the background, the technologies necessary for transformation and production. It's about giving SMEs more agility so they can more easily respond to changing demand in terms of the number and type of parts ordered. To do so, you need teams that are much more responsive. We talked about this with the heads of the Chamber of Commerce CCIJ, including the new president Georges Humard. They confirmed that the areas they are interested in are design thinking, agility and lean processes. There will be many seminars, courses, awareness raising events and support.

When it comes to healthcare, what are we talking about exactly?

We have developed three areas through numerous meetings with Professor Zeilhofer, the Jura Hospital and the Chamber of Commerce. The first area will be pure medical technology, with implants and 3D printing, specialisms very close to the Jura's know-how. This will be the biggest focus. The second will be what they call health-tech, which involves connectivity and digital health. Jura Hospital and the Public Health Service believe that there's much to do in the canton. The third area is the health system. Both the Health and Economy Minister, Jacques Gerber, and Nicolas Pétremand are convinced that the Jura's relatively small health system means it can experiment and innovate much more quickly than in other cantons.

Your list also includes setting up projects, funding, leadership, working methods…

We are working to release funds at cantonal level as well as supporting businesses in securing funding at federal level. We have promised to provide them with people who can navigate the bureaucracy of innovation funds, so they can access this funding faster.

What's so special about Jura business culture?

Here, discretion is above anything else. The Jura entrepreneur does everything himself. As a result, there's little visibility of the skills that Jura businesses have. When we speak to businesses from the biomedical engineering group at Allschwil, they often ask us to help them find the right skills in the Jura for their projects. People know that there is a lot of know-how in the Jura, but they don't know how to access it. This suggests businesses must do more to make their skills known. With the Chamber of Commerce, we're going to link up with Basel-Stadt and Basel-Landschaft. An informal group that includes businesspeople, the Jura Hospital and universities will support the innovation park.

Is there a lack of access to a community and network of innovators and experts for research and development in the canton of Jura?

Yes. There is a real appetite for working with the University of Basel, the FHNW School of Engineering and HE Arc at Neuchâtel on the technology side of things. I think that we will be able to create links between Jura entrepreneurs and universities. The clients of Jura entrepreneurs also want these entrepreneurs to collaborate with the universities, we've been told. There is a lot more innovation than people think. Every time I visit a Jura business, I am amazed by the level of innovation. I think it's great to see that, when you talk to Jura businesspeople, they have lots of pragmatism for moving forward.

Interview: Georges Maillard, Le Quotidien Jurassien

report Medtech

Basel startup Nutrix beats 900 startups

11.11.2019

event Entrepreneurship

Seminar Vorbereitung zur Firmengründung

Date: 27.11.2019

Place: Tenum Liestal, Grammetstrasse 14, 4410 Liestal

Cookies

BaselArea.swiss uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.

Ok